
NTHI Stock Forecast & Price Target
NTHI Analyst Ratings
Bulls say
NeOnc Technologies Hldgs is a biopharmaceutical company with a promising focus on developing targeted treatments for difficult-to-treat brain tumors. Their financials have improved, and their promising lead drugs, NEO100 and NEO212, coupled with their innovative drug delivery methods, give them a bullish outlook for future success. Along with favorable safety profiles and potential for treating anemia and drug resistance, NeOnc Technologies Hldgs faces typical risks and is valued through a DCF analysis for future growth.
Bears say
NeOnc Technologies Hldgs is a clinical-stage biopharmaceutical company that is developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system (CNS) diseases. While their lead product candidates, NEO100 and NEO212, show promise in treating glioblastoma and other types of brain cancer, there are concerns regarding regulatory scrutiny and the company's ability to successfully develop and commercialize these products. Additionally, the company's financials and stock performance have been lackluster, making it a risky investment at this time.
This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
NTHI Analyst Forecast & Price Prediction
Start investing in NTHI
Order type
Buy in
Order amount
Est. shares
0 shares